Will Advise on Clinical Trial Design for Dry AMD and Stargardt's Treatment
LaFayette, NY – Ichor Therapeutics, Inc. (Ichor Therapeutics) is pleased to announce that it has recruited one of the world’s top experts in retinal disease, Dr. José-Alain Sahel, M.D., to join its Advisory Board regarding LYSOCLEAR™, a pre-clinical drug candidate in development by its affiliate, Lysoclear, Inc. (Lysoclear), for the treatment of age-related macular degeneration (AMD) and Stargardt’s macular degeneration.
Dr. Sahel is known worldwide for his expertise in vision restoration techniques. He has developed several interventions for retinitis pigmentosa, age-related macular degeneration, vascular eye disease, and other vision impairments that currently are untreatable, and is a co-inventor on more than 40 patents.
Dr. Sahel is the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, the director of the UPMC Eye Center, and also serves as the Chair of Ophthalmology for the Eye and Ear Foundation of Pittsburgh. He is also the founder and director of the Vision Institute in Paris and a professor at the Sorbonne’s medical school Université Pierre-et-Marie-Curie.
“We are extremely pleased to be adding someone of Dr. Sahel’s caliber and experience to our Advisory Board,” said Kelsey Moody, MBA, and CEO of both Ichor Therapeutics and Lysoclear. “We have no doubt that Dr. Sahel’s expertise will allow us to develop reliable, consistent protocols for our clinical trials and that his impact on our Board will be immediate and enduring.”
As an Advisory Board member, Dr. Sahel will advise on the clinical trial design for therapies that Lysoclear is developing for dry AMD and Stargardt's macular degeneration, including the LYSOCLEAR™ drug candidate. He has overseen more than 50 clinical trials, many of which are focused on retinal implants, gene therapy, and other advanced biomedical technologies. Dr. Sahel also heads the French National Reference Center for Retinal Dystrophies and chairs a network of more than 90 European clinical trial centers focused on retinal diseases. The drug candidate LYSOCLEAR™ is now being evaluated in pre-clinical animal models for safety and efficacy. Lysoclear expects to be prepared to begin human clinical trials for LYSOCLEAR™ in 2018.
About Ichor Therapeutics
Ichor Therapeutics, Inc. is a pre-clinical biotechnology company located in LaFayette, NY. Ichor Therapeutics has several intramural research programs that broadly focus on therapeutic interventions for age-related disease. Ichor Therapeutics is eager to engage collaborators in industry and academia who share its vision of delivering the next generation of therapies for the illnesses of aging. For more information, please visit www.ichortherapeutics.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, and is subject to the Safe Harbor within such laws. This press release contains statements about expected future events that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Ichor Therapeutics, Inc. and Lysoclear, Inc. to be materially different from the statements made herein.